Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.59% $3.39
America/New_York / 12 des 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 92.95 mill |
EPS: | -1.140 |
P/E: | -2.97 |
Earnings Date: | Mar 28, 2024 |
SharesOutstanding: | 27.42 mill |
Avg Daily Volume: | 0.163 mill |
RATING 2023-12-22 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.97 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.51x |
Company: PE -2.97 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 3.32 - 3.46 ( +/- 2.18%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-12 | United Therapeutics Corp | Sell | 0 | Common Stock |
2023-12-12 | Heine Lisa Wipperman | Sell | 66 943 | Common Stock |
2023-12-13 | Heine Lisa Wipperman | Sell | 67 413 | Common Stock |
2023-12-12 | Maag Peter | Sell | 62 092 | Common Stock |
2023-12-13 | Maag Peter | Sell | 58 368 | Common Stock |
INSIDER POWER |
---|
-56.45 |
Last 96 transactions |
Buy: 3 749 163 | Sell: 3 803 884 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.39 (0.59% ) |
Volume | 0.632 mill |
Avg. Vol. | 0.163 mill |
% of Avg. Vol | 387.41 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.